key: cord-0864180-gx3ydxfx authors: Wand, Ori; Mor, Orna; Zuckerman, Neta; Fadeela, Ayman; Benchetrit, Sydney; Nacasch, Naomi; Cohen-Hagai, Keren title: Outcomes From Infections With Variant Strains of SARS-CoV-2 Among Patients Receiving Maintenance Hemodialysis date: 2021-07-15 journal: Am J Kidney Dis DOI: 10.1053/j.ajkd.2021.06.015 sha: 36791857654f2ce0ef0c9a8e807c8c3062bbb61a doc_id: 864180 cord_uid: gx3ydxfx nan Even though safe and effective vaccines have been developed for SARS-CoV-2, variants of concern continue to emerge. 1, 2 We present a comparison of two COVID-19 waves in two hemodialysis centers. Patients in one hemodialysis center ("wave 1") were infected by nonvariant SARS-CoV-2 between July and October 2020. Patients from the second center ("wave 2") became ill between December 28, 2020, and January 10, 2021 and were infected by variant SARS-CoV-2 from the B.1.362 lineage, Israeli Variant Under Investigation with L452R mutation (IVUI-L452R). Genetic mutations were detected by next generation sequencing. Detailed descriptions of methods and timelines figures appears in S1. Methods. A total of 33 patients were included in this analysis, 26 from wave 1 and 7 from wave 2. Baseline clinical characteristics were similar between the groups except for a higher frequency of diabetes mellitus and heart failure among wave 1 patients (Table S1) . Clinical presentation and disease severity are compared in Table 1 and Figure 1 . Five of 26 patients from wave 1 were asymptomatic and diagnosed by post-exposure surveillance, while all patients from wave 2 were symptomatic. COVID-19 severity was significantly worse in patients from wave 2, with more patients classified as critical COVID-19 (71% vs. 8%, p=0.005, Figure 1 ), as well as higher needs for non-invasive ventilation (p=0.05), mechanical ventilation (p=0.05), and hemodynamic support (p=0.05). Medical treatment is detailed in Table S2 . In-hospital mortality was significantly higher among patients from wave 2 than from wave 1 (57% vs. 8%, p<0.005), corresponding to an OR of 16 (95% confidence interval 2-127.9). Overall mortality was also significantly higher for wave 2 patients despite shorter follow-up duration, as compared to wave 1 patients: 71.4% during 39±4 days vs. 15.4% during 129±54 days (p<0.001 and 0.003, respectively). In this retrospective study, patients infected with IVUI-L452R SARS-CoV-2 had significantly poorer outcomes, including greater need for respiratory and hemodynamic support, and higher mortality. COVID-19 caused by variant viruses differed from the onset, as all patients were symptomatic with more malaise and confusion, and worse laboratory findings at presentation. Since all hemodialysis patients were screened for SARS-CoV-2 following outbreaks, we believe that all cases, including asymptomatic, were diagnosed. Concerns regarding SARS-CoV-2 variants relate to increased infectivity by some strains, 3, 4 potential resistance to vaccines, and emerging data relating specific genetic mutations to virulence. 5 However, varying medical capabilities and standards between different facilities, and patients' heterogenicity can significantly confound such associations. Therefore, data from specific patient populations treated at the same medical facility can add meaningful information. Patients from wave 2 were infected by SARS-CoV-2 from B.1.362 lineage with an additional L452R mutation in the spike gene. Two other mutations associated with this variant are Q57H in Orf3a, and T261I in Orf1 proteins. Both are associated with the globally prevalent viral clade 20C commonly observed in Israel and worldwide. This variant is suspected by the Israeli Ministry of Health to be a potential variant of concern, and as such is currently defined as IVUI- The Q57H mutation in Orf3a may be associated with increased infection rates and higher mortality. 6 The L452R mutation in the Spike protein alters its interface, promotes stronger virus-J o u r n a l P r e -p r o o f cell attachment through ACE2, and increases infectivity. 7 This supports plausible mechanisms that can explain the deleterious effects of infection with variant viruses. Major limitations of this study include its retrospective nature and small sample size. Rates of heart failure and diabetes, risk factors for critical COVID-19, 9 were higher among subjects from wave 1. Since this was not a controlled trial and because of continually emerging data, different therapeutic approaches were used during each wave. Convalescent plasma was used in wave 1 although accumulated data have failed to ascertain a therapeutic benefit of this therapy. 10 Glucocorticoids, which significantly reduce mortality from severe COVID-19, 9 were used more often in wave 2. Thus, differences in co-morbidities and treatment were unlikely to explain differences in outcomes between the two waves. Additionally, comprehensive mutation analysis was not performed for all wave 1 patients. However, several samples tested negative for variants of concern as part of outbreak surveillance, and the mutations identified in the variant viruses were very uncommon in Israel during the outbreak in Center 2 . 8 and unpublished data Finally, the different outcomes could not be explained by variations in national morbidity and mortality rates, which were comparable between the waves (Figures S1-S2) . Despite these limitations, our findings that relate viral genetic variation to clinical outcomes will inform future investigations. All patients were treated in a single medical center, which strengthens our results. Of note, no hemodialysis patients have been treated for COVID-19 in our hospital since February 2021, following nationwide vaccination, prioritizing hemodialysis patients. We believe this should encourage vaccination of this population in other countries. In addition, previous reports of COVID-19 in hemodialysis patients demonstrated highly variable outcomes. We believe genetic typing of SARS CoV-2 infection may prove important in interpreting outcomes in future studies. Item S1. Methods Table S1 . Baseline characteristics of study population Table S2 . COVID-19 treatment of study population Disease severity was ranked according to National Institute of Health guidelines as asymptomatic, mild, moderate (with clinical or radiographic evidence of lower respiratory tract disease and oxygen saturation ≥94% while breathing room air), severe (saturation <94%, respiratory rate >30/min, infiltrates over 50% of lungs volume) or critical (requiring invasive or non-invasive ventilation, in shock, or with organ failure) (Item S1). Distribution of severity differed significantly between patients in Wave 1 and Wave 2, p=0.005. J o u r n a l P r e -p r o o f An action plan for pan-European defence against new SARS-CoV-2 variants New variant of SARS-CoV-2 in UK causes surge of COVID-19 Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus Emergence of a Highly Fit SARS-CoV-2 Variant Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study ORF3a mutation associated with higher mortality rate in SARS-CoV-2 infection Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers recent massive expansion of SARS-Cov-2 variants. bioRxiv. Preprint posted online Full genome viral sequences inform patterns of SARS-CoV-2 spread into and within Israel Severe Covid-19 A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia We thank Faye Schreiber, MS (Meir Medical Center) for editing the manuscript.